Ethics/Regulatory

Determining the best way to redact sensitive material prior to disclosure

Friday, May 15, 2015

Transparency and disclosure of clinical trial information has been growing in importance. Providing previously confidential clinical study results for public consumption is a key step toward increasing trust between the public and the industry and encouraging information sharing that could lead to new products or therapeutic approaches.

[Read More]

EMA tightens rules on ‘revolving door’ for committee members and experts

Thursday, May 7, 2015

The EMA has updated its rules on declarations of interests for scientific committee members and experts. The updates further strengthen EMA’s policy by restricting involvement of experts in the scientific assessment of medicines if they plan to take up a job in the pharmaceutical industry. The updates also include a revised guide on how to complete the agency’s declaration of interest form.

[Read More]